Naringenin ntxiv tsis pub Barrier hnyuv tsis xws luag thiab o rau nas Colitic

Hnyuv barrier tsis xws luag yog koom tes nrog rau lub pathogenesis inflammatory plob tsis so tswj kab mob. Txoj kev tshawb no tam sim no yuav tshawb xyuas lub ameliorative los ntawm naringenin, citrus polyphenol, nyob los tsis xws luag barrier hnyuv hlws ris kaw ntom nti (TJ) thiab muaj mob nyob rau hauv tus qauv ntawm plab murine. Thaum Expt. 1, siv ib 2 × 2 fractional tsim, cov nas tsuag tau siv dej los yog 2% dextran sulfate sodium (DSS) nrog noj tiv thaiv los yog naringenin uas muaj cov pluas noj rau 9 d (mob theem). DSS coj los nyuv puas tsuaj heev thiab o, raws li qhia ntawm lub cev poob, si soj ntsuam qhov ncauj tawm, cov roj shortening nyuv thiab noob kab zauv uas inflammatory cytokines [interferon-γ, interleukin (IL)-6, macrophage inflammatory protein ntau-2, thiab IL-17A). DSS koom haum saib xyuas kuj hnov TJ barrier tshaj nyob hauv cov nyuv, raws li qhia ntawm muaj nyuv permeability thiab ntshav LPS-ruaj protein ntau ntau ntau, uas ua los ntawm cov impaired colonic qhia ntawm cov nqaijrog TJ, occludin, junctional adhesion molecule-A, thiab claudin-3.



Txhawb noj nrog naringenin lig los yog cov attenuated cov tsos mob, suggesting ntawd naringenin ameliorates tus DSS hob plab kawg cov los ntawm kev tiv thaiv ntawm tus TJ barrier. 2 Expt., analyses twb tau nyob rau ntau cov kab mob (d 3, 6, thiab 9) los saib dua plhuav lub luag hauj lwm ameliorative uas naringenin rau ntawm qhov pib thiab muaj mob plab. DSS koom haum saib xyuas mob pesnrab vim raug yuam roj shortening nyuv ntawm d 3 thiab 6 thiab ntau zog tus mob yam Performance index (DAI) thiab cov yeeb yam inflammatory cytokine (IL-6 thiab IL-17A) yam tsis muaj teeb meem loj qab hauv colonic permeability. Noj naringenin attenuated tus muaj zog DAI thiab cov nyuv shortening, cov thiab tended rau suppress cov cytokine kom qhia. Cov kev tshawb pom hais tias muaj cov kev ntxiv mechanism underlying lub naringenin-mediated, anticolitic nyhuv nrog rau txoj kev tiv thaiv barrier.